Combined riluzole and sodium phenylbutyrate therapy in transgenic amyotrophic lateral sclerosis mice

Amyotrophic Lateral Sclerosis

Volumn 10, Issue 2, 2009, Pages 85-94

  Del Signore, Steven J ^a   Amante, Daniel J ^a   Kim, Jinho ^a,b   Stack, Edward C ^a,b   Goodrich, Sarah ^a   Cormier, Kerry ^b   Smith, Karen ^a,b   Cudkowicz, Merit E ^c   Ferrante, Robert J ^a,b  

^a BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b New England Veterans Administration   (United Kingdom)

^c MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

Amyotrophic lateral sclerosis; Histone deacetylase inhibition; Riluzole; Sodium phenylbutyrate; Therapy

Indexed keywords

4 PHENYLBUTYRIC ACID; HISTONE DEACETYLASE INHIBITOR; HISTONE H4; PROTEIN P50; RILUZOLE;

ACETYLATION; AMYOTROPHIC LATERAL SCLEROSIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ASTROCYTOSIS; BODY WEIGHT; CELL DEATH; CONTROLLED STUDY; DRUG POTENTIATION; DRUG RESPONSE; GRIP STRENGTH; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; SPINAL CORD ATROPHY; SURVIVAL TIME; TRANSGENIC MOUSE;

ACETYLATION; AMYOTROPHIC LATERAL SCLEROSIS; ANIMALS; ANTERIOR HORN CELLS; BODY WEIGHT; DRUG SYNERGISM; DRUG THERAPY, COMBINATION; FEMALE; HISTONES; HUMANS; MALE; MICE; MICE, TRANSGENIC; MUSCLE STRENGTH; NEUROPROTECTIVE AGENTS; NF-KAPPA B P50 SUBUNIT; PHENOTYPE; PHENYLBUTYRATES; RILUZOLE; SUPEROXIDE DISMUTASE;

EID: 62549133620     PISSN: 17482968     EISSN: 1471180X     Source Type: Journal    
DOI: 10.1080/17482960802226148     Document Type: Article

References (47)

1. Rowland, L. and Schneider, N. (2001) Amyotrophic lateral sclerosis. N Engl J Med., 344, pp. 1688-1700.
2. Rosen, DR, Siddique, T., Patterson, D., Figlewicz, DA, Sapp, P. Hentati, A. et al. (1993) Mutations in Cu/Zn superoxide dismutase gene are associated with familial amyotrophic lateral sclerosis. Nature., 362, pp. 59-62.
3. Andersen, PM, Sims, KB, Xin, WW, Kiely, R., O'Neill, G. Ravits, J. et al. (2003) Sixteen novel mutations in the Cu/Zn superoxide dismutase gene in amyotrophic lateral sclerosis: A decade of discoveries, defects and disputes. Amyotroph Lateral Scler Other Motor Neuron Disord., 4, pp. 62-73.
4. Gurney, ME, Pu, H., Chiu, AY, Dal Canto, MC, Polchow, CY Alexander, DD et al. (1994) Motor neuron degeneration in mice that express a human Cu/ Zn superoxide dismutase mutation. Science., 264, pp. 1772-1775.
5. Ryu, H. and Ferrante, RJ. (2007) Translational therapeutic strategies in amyotrophic lateral sclerosis. Mini Rev Med Chem., 7, pp. 141-150.
6. DiBernardo, AB and Cudkowicz, ME. (2006) Translating preclinical insights into effective human trials in ALS. Biochim Biophys Acta., 1762, pp. 1139-1149.
7. Gurney, ME, Fleck, TJ, Himes, CS and Hall, ED. (1998) Riluzole preserves motor function in a transgenic model of familial amyotrophic lateral sclerosis. Neurology., 50, pp. 62-66.
8. Ryu, H., Smith, K., Camelo, SI, Carreras, I., Lee, J. Iglesias, AH et al. (2005) Sodium phenylbutyrate prolongs survival and regulates expression of anti-apoptotic genes in transgenic amyotrophic lateral sclerosis mice. J Neurochem., 93, pp. 1087-1098.
9. Wu, AS, Kiaei, M., Aguirre, N., Crow, JP, Calingasan, NY Browne, SE et al. (2003) Iron porphyrin treatment extends survival in a transgenic animal model of amyotrophic lateral sclerosis. J Neurochem., 85, pp. 142-150.
10. Klivenyi, P., Ferrante, RJ, Matthews, RT, Bogdanov, MB, Klein, AM Andreassen, OA et al. (1999) Neuroprotective effects of creatine in a transgenic animal model of amyotrophic lateral sclerosis. Nat Med., 5, pp. 347-350.
11. Olney, JW and de Gubareff, T. (1978) Glutamate neurotoxicity and Huntington's chorea. Nature., 271, pp. 557-559.
12. van den Bosch, L, van Damme, P., Bogaert, E. and Robberecht, W. (2006) The role of excitotoxicity in the pathogenesis of amyotrophic lateral sclerosis. Biochim Biophys Acta., 1762, pp. 1068-1082.
13. Bensimon, G., Lacomblez, L. and Meininger, V. (1994) A controlled trial of riluzole in amyotrophic lateral sclerosis. N Engl J Med., 330, pp. 585-591.
14. Lacomblez, L., Bensimon, G., Leigh, PN, Guillet, P. and Meininger, V. (1996) Dose-ranging study of riluzole in amyotrophic lateral sclerosis. Lancet., 347, pp. 1425-1431.
15. Doble, A. (1996) The pharmacology and mechanism of action of riluzole. Neurology., 47, p. S233.
16. Martin, D., Thompson, MA and Nadler, JV. (1993) The neuroprotective agent riluzole inhibits release of glutamate and aspartate from slices of hippocampal area CA1. Eur J Pharmacol., 250, pp. 473-476.
17. Wang, SJ, Wang, KY and Wang, WC. (2004) Mechanisms underlying riluzole inhibition of glutamate release from rat cerebral cortex nerve terminals (synaptosomes). Neuroscience., 125, pp. 191-201.
18. Albo, F., Pieri, M. and Zona, C. (2004) Modulation of AMPA receptors in spinal motor neurons by the neuroprotective agent riluzole. J Neurosci Res., 78, pp. 200-207.
19. Hubert, JP, Delumeau, JC, Glowinski, J., Premont, J. and Doble, A. (1994) Antagonism by riluzole of entry of calcium evoked by NMDA and veratridine in rat cultured granule cells: Evidence for a dual mechanism of action. Br J Pharmacol., 113, pp. 261-267.
20. Fumagalli, E., Bigini, P., Barbera, S., de Paola, M. and Mennini, T. (2006) Riluzole, unlike the AMPA antagonist RPR119990, reduces motor impairment and partially prevents motor neuron death in the wobbler mouse, a model of neurodegenerative disease. Exp Neurol., 198, pp. 114-128.
21. Kriz, J., Gowing, G. and Julien, JP. (2003) Efficient three-drug cocktail for disease induced by mutant superoxide dismutase. Ann Neurol., 53, pp. 429-436.
22. Snow, RJ, Turnbull, J., da Silva, S., Jiang, F. and Tarnopolsky, MA. (2003) Creatine supplementation and riluzole treatment provide similar beneficial effects in copper, zinc superoxide dismutase (G93A) transgenic mice. Neuroscience., 119, pp. 661-667.
23. Waibel, S., Reuter, A., Malessa, S., Blaugrund, E. and Ludolph, AC. (2004) Rasagiline alone and in combination with riluzole prolongs survival in an ALS mouse model. J Neurol., 251, pp. 1080-1084.
24. Graf, M., Ecker, D., Horowski, R., Kramer, B., Riederer, P. Gerlach, M. et al. (2005) High dose vitamin E therapy in amyotrophic lateral sclerosis as add-on therapy to riluzole: Results of a placebo-controlled double-blind study. J Neural Transm., 112, pp. 649-660.
25. Malaspina, A., Kaushik, N. and De Beleroche, J. (2001) Differential expression of 14 genes in amyotrophic lateral sclerosis spinal cord detected using gridded cDNA arrays. J Neurochem., 77, pp. 132-145.
26. Ishigaki, S., Niwa, J., Ando, Y., Yoshihara, T., Sawada, K. Doyu, M. et al. (2002) Differentially expressed genes in sporadic amyotrophic lateral sclerosis spinal cords: Screening by molecular indexing and subsequent cDNA microarray analysis. FEBS Lett., 531, pp. 354-358.
27. Gonzalez de Aguilar, JL, Gordon, JW, Rene, F., de Tapia, M., Lutz-Bucher, B. Gaiddon, C. et al. (2000) Alteration of Bcl-x/Bax ratio in a transgenic mouse model of amyotrophic lateral sclerosis: Evidence for the implication of the p53 signaling pathway. Neurobiol Dis., 7, pp. 406-415.
28. Olsen, MK, Roberds, SL, Ellerbrock, BR, Fleck, TJ, McKinley, DK and Gurney, ME. (2001) Disease mechanisms revealed by transcription profiling in SOD1-G93A transgenic mouse spinal cord. Ann Neurol., 50, pp. 730-740.
29. Cremer, JE, Lai, JC and Sarna, GS. (1977) Rapid blood brain transport and metabolism of butyrate and pyruvate in the rat after portocaval anastomosis. J Physiol., 266, pp. 70-71.
30. Collins, AF, Pearson, HA, Giardina, P., McDonagh, KT, Brusilow, SW and Dover, GJ. (1995) Oral sodium phenylbutyrate therapy in homozygous beta thalassemia: A clinical trial. Blood., 85, pp. 43-49.
31. Vigushin, DM and Coombes, RC. (2002) Histone deacetylase inhibitors in cancer treatment. Anticancer Drugs., 13, pp. 1-13.
32. Cudkowicz, ME, Andres, PL, Schoenfeld, D., Zhang, H., Sherman, A. Yu, H. et al. (2007) Safety and dose escalating study of oral sodium phenylbutyrate in subjects with ALS. Neurology., 68, p. A90.
33. Ferrante, RJ, Klein, AM, Dedeoglu, A. and Beal, MF. (2001) Therapeutic efficacy of EGb761 (Gingko biloba extract) in a transgenic mouse of amyotrophic lateral sclerosis. J Mol Neurosci., 17, pp. 89-96.
34. Wang, CY, Mayo, MW and Baldwin Jr, AS. (1996) TNF- and cancer therapy-induced apoptosis: Potentiation by inhibition of NF-kappa B. Science., 274, pp. 784-787.
35. Mayo, MW, Denlinger, CE, Broad, RM, Yeung, F., Reilly, ET Shi, Y. et al. (2003) Ineffectiveness of histone deacetylase inhibitors to induce apoptosis involves the transcriptional activation of NF-kB through the Akt pathway. J Biol Chem., 278, pp. 18980-18989.
36. Pennypacker, KR, Kassed, CA, Eidizadeh, S., Saporta, S., Sanberg, PR and Willing, AE. (2001) NF-kB p50 is increased in neurons surviving hippocampal injury. Exp Neurol., 172, pp. 307-319.
37. Bruijn, LI, Miller, TM and Cleveland, DW. (2004) Unraveling the mechanisms involved in motor neuron degeneration in ALS. Annu Rev Neurosci., 27, pp. 723-749.
38. Choudry, RB and Cudkowicz, ME. (2005) Clinical trials in amyotrophic lateral sclerosis: The tenuous past and the promising future. J Clin Pharmacol., 45, pp. 1334-1344.
39. Shefner, JM, Cudkowicz, ME, Schoenfeld, D., Conrad, T., Taft, J. Urbinelli, L. et al. (2004) A clinical trial of creatine in ALS. Neurology., 63, pp. 1656-1661.
40. Huntington Study Group (2001) A randomized, placebo-controlled trial of coenzyme Q10 and remacemide in Huntington's disease. Neurology, 57, pp. 397-404.
41. Shults, CW, Oakes, D., Kieburtz, K., Beal, MF, Haas, R. Plumb, S. et al. (2002) Effects of coenzyme Q10 in early Parkinson's disease: Evidence of slowing of the functional decline. Arch Neurol., 59, pp. 1541-1550.
42. Ferrante, KL, Shefner, J., Zhang, H., Betensky, R., O'Brien, M. Yu, H. et al. (2005) Tolerance of high-dose (3000 mg/day) coenzyme Q10 in ALS. Neurology., 65, pp. 1834-1836.
43. Egorin, MJ, Yuan, ZM, Sentz, DL, Plaisance, K. and Eiseman, JL. (1999) Plasma pharmacokinetics of butyrate after intravenous administration of sodium butyrate or oral administration of tributyrin or sodium butyrate to mice and rats. Cancer Chemother Pharmacol., 43, pp. 445-453.
44. Chang, J-G, Hsieh-Li, H-M, Jong, Y-J, Wang, NM, Tsai, CH and Li, H. (2001) Treatment of spinal muscular atrophy by sodium butyrate. Proc Natl Acad Sci., 98, pp. 9808-9813.
45. Ferrante, RJ, Kubilus, JK, Lee, J., Ryu, H., Beesen, A. Zucker, B. et al. (2003) Histone deacetylase inhibition by sodium butyrate chemotherapy ameliorates the neurodegenerative phenotype in Huntington's disease mice. J Neurosci., 23, pp. 9418-9427.
46. Warrell, RPJr, He, LZ, Richon, V., Calleja, E. and Pandolfi, PP. (1998) Therapeutic targeting of transcription in acute promyelocytic leukemia by use of an inhibitor of histone deacetylase. J Natl Cancer Inst., 90, pp. 1621-1625.
47. Gilbert, J., Baker, SD, Bowling, MK, Grochow, L., Figg, WD Zabelina, Y. et al. (2001) A phase I dose escalation and bioavailability study of oral sodium phenylbutyrate in patients with refractory solid tumor malignancies. Clin Cancer Res., 7, pp. 2292-2300.